DURHAM, N.C., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ: NOVN ) today announced that results from the Company’s Phase 2b clinical trial to evaluate the efficacy and safety of topical nitric oxide-releasing product candidate SB204 gel for the treatment of acne vulgaris, or acne, will be presented at the 35 th Anniversary Fall Clinical Dermatology Conference in Las Vegas. This presentation will include the results of efficacy assessments and additional data regarding the tolerability of SB204 throughout the 12-week trial.
“In more than 30 years of experience as a dermatologist, I have seen firsthand how the tolerability of a topical acne product drives patient compliance," said M. Joyce Rico, MD, Chief Medical Officer of Novan. “The safety and tolerability profile observed in the Phase 2b clinical trial with SB204 was excellent. Of all five tolerability assessments, the burning/stinging and scaling categories reflected the most notable difference between active and vehicle. Patients treated with SB204 rarely developed moderate ( < 3%) or severe (1%) burning/stinging at any point during treatment, while the incidence of moderate scaling never exceeded 1%.”
Novan announced in September that the Company’s two, identically designed Phase 3 pivotal clinical trials for SB204 were fully enrolled. Novan expects to report top-line results from these Phase 3 trials in the first quarter of 2017.
About the Presentation
Title: “Efficacy and Safety of SB204 Gel in the Treatment of Acne Vulgaris” Lead Author: Lawrence Eichenfield, MD, Chief of Pediatric and Adolescent Dermatology at San Diego Children’s Hospital and Clinical Professor of Pediatrics and Medicine at the University of California, San Diego School of Medicine Abstract/Poster Number: to be assigned at the start of the Conference Dates: Thursday-Sunday, Oct. 20-23, 2016
About Novan
Novan, Inc. is a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide-releasing platform. Nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated, first-in-class product candidates. We are rapidly advancing programs in five dermatological conditions with significant unmet medical need. We believe that our ability to conveniently deploy nitric oxide on demand in topical formulations allows us the potential to significantly improve patient outcomes in a variety of skin diseases and positions us to be a commercially successful leader in the dermatology market.
For more information, visit the Company’s website at www.Novan.com .
Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, statements related to pharmaceutical development of nitric oxide-based product candidates and future prospects. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from our expectations. These forward-looking statements speak only as of the date of this press release, and Novan disclaims any intent or obligation to update these forward-looking statements, except as expressly required by law.
CONTACT:
(Investors) Sean Andrews, Senior Director of Investor Relations Novan, Inc. 919-627-6847 investors@novan.com
(Media) Deb Holliday Pascale Communications, LLC 412-877-4519 deb@pascalecommunications.com
